In a bold move set to reshape the pharmaceutical landscape, AstraZeneca has announced a substantial $3.5 billion investment aimed at expanding its research and manufacturing footprint across the United States by the end of 2026. This strategic initiative underscores the company’s commitment to enhancing its presence in its largest market, which currently accounts for 44% […]
AstraZeneca PLC unveiled its financial results for the fiscal year and fourth quarter of 2023 on 8 February 2024, marking a year of robust growth and significant progress in its product pipeline. With three new medicines approved since the third quarter, the pharmaceutical giant’s revenues and earnings per share (EPS) saw considerable increases, reflecting its […]
AstraZeneca has announced the launch of Evinova, poised to become a leading provider in the digital health solutions domain. Backed by AstraZeneca and collaborating with Parexel and Fortrea, Evinova aims to deliver globally-scaled digital products and services to the life sciences and healthcare sectors. Evinova’s primary focus will be on marketing proven digital technology solutions, […]
AstraZeneca has announced its financial results for the nine months (9M) and third quarter (Q3) of 2023, displaying solid financial performance with a focus on non-COVID-19 medicines. Financial Summary and Performance In 9M 2023, AstraZeneca reported total revenue of $33,787 million, a 5% increase, with a notable decline of $2,896 million from COVID-19 medicines. Excluding […]
AstraZeneca said that it will invest $360 million in Ireland for setting up an active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin. The UK-based pharma giant said that the API manufacturing plant at the Alexion Campus in College Park will help ensure that its supply network around the world is fit for […]
AstraZeneca has secured its shareholders’ approval for its previously announced $39 billion acquisition of US biopharma company Alexion Pharmaceuticals. The pharma giant expects the acquisition to be completed in the third quarter of this year with the transaction subject to approval from Alexion’s shareholders, certain regulatory approvals, and also other customary closing conditions. Commenting on […]
AstraZeneca has agreed to supply the US government with up to half a million additional doses of AZD7442, the company’s Covid-19 antibody candidate, for a sum of $205 million. In this connection, AstraZeneca has modified an existing agreement with the US Department of Health and Human Services (HHS) and the US Department of Defense (DoD). […]
AstraZeneca acquisition of Alexion Pharmaceuticals : Pharma giant AstraZeneca has signed a $39 billion deal to acquire Alexion Pharmaceuticals, a US biopharma company engaged in developing therapies for rare disorders. As per the terms of the deal, Alexion Pharmaceuticals’ shareholders will be paid $60 in cash and 2.1243 American Depositary Shares (ADSs) of AstraZeneca, valuing […]
AstraZeneca said that clinical trials for the AZD1222 Covid-19 vaccine candidate, have resumed in various parts of the world after regulators across the US, UK, Brazil, Japan, and South Africa confirmed that it was safe to continue them. The US Food and Drug Administration (FDA) has authorized the restart of AZD1222 clinical trials in the […]
AstraZeneca said that AZD7442, which is being developed for the prevention and treatment of Covid-19, will move into two phase 3 clinical trials. AZD7442 is a combination of a couple of monoclonal antibodies (mAbs) extracted from convalescent patients with SARS-CoV-2 infection. It will be assessed in more than 6,000 participants at sites in and outside […]